Podcast 765: Phenobarbital for Alcohol Withdr...

Contributor: Aaron Lessen, MD Educational Pearls: How long do we need to watch patients with a presumed overdose who were treated with naloxone in the field? A 2025 study in the Annals of Emergency Medicine took a look at this question Methods Prospective, multi-institutional coh ...  Show more

Contributor: Travis Barlock, MD Educational Pearls: D-dimer: fibrin degradation product used to evaluate for clot formation and breakdown Threshold: <500ng/mL rules out venous thromboembolism in low risk patients Elevated D-dimer indicates recent or ongoing intravascular coagulat ...  Show more

<div>Learn from an expert panel in addiction medicine about a potpourri of fascinating topics, with updated data to guide clinical decision-making.  We picked the brains of physicians Stefan Kertesz, Ximena Levander, Kenny Morford, and Katherine Mullins to learn about th ...  Show more

Dominate opioid and xylazine (aka tranq) withdrawal in the hospital with expert insights from Dr. Joseph D’Orazio (@dorazepam) recorded LIVE! at Pennsylvania Hospital Grand Rounds in Philadephia, PA. Xylazine, an alpha-2 adrenergic agonist, has emerged as a frequent contaminant i ...  Show more

In this episode, Kyle and Joe interview Ben Sessa, a Consultant Psychiatrist. Ben comes on the show to talk about preliminary results from the first ever, MDMA assisted therapy for alcohol use disorder (AUD).

Join Dan McCollum and EM clinical pharmacist RJ LaCoursiere as they discuss the use of buprenorphine for the treatment of Opioid Use Disorder. Who should be considered for treatment with Medication-Assisted Treatment (MAT)? Why should it be avoided if the patient isn't in acute w ...  Show more